SAN DIEGO, CA (March 19, 2007) Zogenix, Inc., a privately held neuroscience-focused specialty pharmaceutical company, announced today it has received $3.5 million of a $10 million loan facility with GE Healthcare Financial Services. Zogenix will use the loan to finance the launch of its first

SAN DIEGO, CA (June 7, 2007) Zogenix, Inc., a privately held CNS-focused specialty pharmaceutical company, announced today that David Nassif has been appointed Executive Vice President and Chief Financial Officer. Mr. Nassif brings a breadth of life science experience across multiple roles,

SAN DIEGO, CA (November 27, 2007) Zogenix, Inc. (”Zogenix”), a private, specialty pharmaceutical company, today announced they have entered into a License Agreement under which Zogenix has been granted exclusive US rights from an affiliate of Elan Corporation, plc (NYSE: ELN) (”Elan”) to develop

SAN DIEGO, CA (January 9, 2008) - Zogenix, Inc. (Zogenix), a private, specialty pharmaceutical company, today announced that the company has raised $18 million in a private placement of preferred stock. The financing was led by Abingworth Management Ltd.

SAN DIEGO, CA (March 17, 2008) : Zogenix, Inc. (”Zogenix”), a private, specialty pharmaceutical company, today announced that it has entered into a license agreement to grant exclusive rights in the European Union to Desitin Pharmaceuticals, GmbH (”Desitin”) to develop and commercialize Zogenix’s

SAN DIEGO, Calif. - (March 19, 2008): Zogenix, Inc. (”Zogenix”), a private, specialty pharmaceutical company, today announced that its New Drug Application (NDA) for sumatriptan DosePro™ has been accepted for filing by the U.S. Food and Drug Administration (FDA).

SAN DIEGO, Calif. - (March 24, 2008): Zogenix, Inc. (”Zogenix”), a private, specialty pharmaceutical company, today announced that it has filed a registration statement with the Securities and Exchange Commission (”SEC”) relating to the proposed initial public offering of shares of its common

SAN DIEGO, Calif. - (April 17, 2008): Zogenix, Inc. (”Zogenix”), a private, specialty pharmaceutical company, today announced that Cynthia “Candy” Robinson has joined the company as Chief Development Officer (CDO), and Mark Thompson has joined as Vice President, Sales and Managed Markets.

SAN DIEGO, Calif. - (June 28, 2008): Zogenix, Inc. (”Zogenix”), a private, specialty pharmaceutical company, today announced that it presented successful results from two clinical studies of sumatriptan DosePro, a product in development for treatment of acute migraine and cluster headache, at the

SAN DIEGO, Calif. - (July 25, 2008): Zogenix, Inc. (”Zogenix”), a privately held, specialty pharmaceutical company, announced today it has closed an $18 million secured loan facility with Oxford Finance Corporation and CIT Healthcare LLC. Zogenix will use the financing proceeds to continue to

- Potential Final Approval July 2009 - SAN DIEGO, Calif. – (February 18, 2009): Zogenix, Inc. (“Zogenix”), a private, specialty pharmaceutical company, announced that the U.S. Food & Drug Administration (FDA) has provided a target date of July 15, 2009 for completion of its review of the NDA

First Product Featuring Novel DosePro Needle-Free Delivery System SAN DIEGO, Calif., (July 16, 2009): Zogenix, Inc. (“Zogenix”), a privately held pharmaceutical company, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA)

— Novel Product Recently Approved by the FDA for Treatment of Acute Migraine and Cluster Headache — SAN DIEGO, CA, and DEERFIELD, IL (August 3, 2009): Zogenix, Inc. (“Zogenix”), a privately held pharmaceutical company and Astellas Pharma US, Inc.

SAN DIEGO, Calif., (September 23, 2009): Zogenix, Inc. (“Zogenix”), a privately held pharmaceutical company, announced today that it has completed a $51 million Series B preferred stock financing. Clarus Ventures and Domain Associates, current investors in Zogenix, co-led the round with

- Data Published in Headache Highlights Bioequivalence, Safety and Ease of Use - SAN DIEGO, CA and DEERFIELD, IL - (October 22, 2009): Zogenix, Inc. (“Zogenix”), a privately held pharmaceutical company, and Astellas Pharma US, Inc. (“Astellas”) announced that positive results from two clinical

- European Pivotal Trial Confirms Bioequivalence - SAN DIEGO, CA and Hamburg, Germany - (October 28, 2009): Zogenix, Inc. (“Zogenix”), a privately held pharmaceutical company, and Desitin Pharmaceuticals GmbH (“Desitin”), a privately held, mid-sized German pharmaceutical company, today announced

- Dr. Arda M. Minocherhomjee of Chicago Growth Partners Joins Zogenix Board of Directors - SAN DIEGO, Calif., (December 7, 2009): Zogenix, Inc. (“Zogenix”), a privately held pharmaceutical company, announced today that it has closed a $35 million second tranche of a Series B preferred stock

− Innovative Needle-Free Delivery System Provides Fast Migraine Relief − SAN DIEGO, Calif. and DEERFIELD, Ill., January 13, 2010 Zogenix, Inc. (“Zogenix”), a privately held pharmaceutical company, and Astellas Pharma U.S., Inc. (“Astellas”) announced today the U.S.

SAN DIEGO, Calif., March 1, 2010 — Zogenix, Inc. (“Zogenix”), a privately held pharmaceutical company, announced the appointment of Ann D. Rhoads to serve as the company’s chief financial officer (CFO). In addition to overseeing the day-to-day financial operations, Ms.

SAN DIEGO, Calif., March 17, 2010 — Zogenix, Inc. (“Zogenix”), a privately held pharmaceutical company, announced that it has initiated a pivotal Phase 3 clinical trial with ZX002, a novel, oral, controlled-release formulation of hydrocodone without acetaminophen.

SAN DIEGO, Calif., July 13, 2010 — Zogenix, Inc. (“Zogenix”), a privately held pharmaceutical company, announced that it has secured a $35 million debt facility led by Oxford Finance Corporation which also included Silicon Valley Bank. The facility consists of a $25 million term loan and a $10

SAN DIEGO, Calif., September 7, 2010 — Zogenix, Inc. (“Zogenix”) announced today that it has filed a registration statement with the Securities and Exchange Commission (”SEC”) relating to the proposed initial public offering of shares of its common stock.

SAN DIEGO, Nov 22, 2010 (GlobeNewswire via COMTEX) -- Zogenix, Inc. ("Zogenix") (Nasdaq:ZGNX) announced today the pricing of its initial public offering of 14,000,000 shares of its common stock at $4.00 per share, before underwriting discounts and commissions.

SAN DIEGO, Nov 30, 2010 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced completion of enrollment in its open-label Phase 3 safety study (Study 802) of ZX002. ZX002 is a novel, oral, single-entity, controlled-release formulation of hydrocodone for the treatment of moderate

SAN DIEGO and HAMBURG, Germany, Dec 2, 2010 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX) and Desitin Pharmaceuticals GmbH today announced that the Danish Medicines Agency of Denmark has approved the Marketing Authorization Application (MAA) for SUMAVEL(R) DosePro(TM) (sumatriptan

SAN DIEGO, Dec 13, 2010 (GlobeNewswire via COMTEX) -- Zogenix, Inc. ("Zogenix") (Nasdaq:ZGNX) today announced that CONNECT, a regional San Diego nonprofit organization, selected SUMAVEL(R) DosePro(TM) (sumatriptan injection) Needle-free Delivery System as a 2010 Most Innovative Product (MIP) winner

SAN DIEGO, Dec 23, 2010 (GlobeNewswire via COMTEX) -- Zogenix, Inc. ("Zogenix") (Nasdaq:ZGNX) announced today that the underwriters of its recently completed initial public offering of common stock have partially exercised their option to purchase shares of common stock from Zogenix to cover

SAN DIEGO and HAMBURG, Germany, Jan 6, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. ("Zogenix") (Nasdaq:ZGNX) and Desitin Pharmaceuticals GmbH ("Desitin") today announced that the Federal Institute for Drugs and Medical Devices of Germany (BrArM), and the Medicines and Healthcare products

SAN DIEGO, Feb 8, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced that Chief Executive Officer Roger L. Hawley, along with Executive Vice President and Chief Financial Officer Ann Rhoads, will participate in the Leerink Swann Hot Topics in Therapeutics Roundtable

SAN DIEGO, Feb 9, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. ("Zogenix") (Nasdaq:ZGNX) today announced that it has received the 2011 Drug Delivery Partnerships(TM) ("DDP") Innovation Award in the Industry Achievement category for SUMAVEL DosePro (sumatriptan injection) Needle-free Delivery

Potential to be First Single-Entity, Controlled Release Hydrocodone Product SAN DIEGO, Feb 10, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX) announced today the completion of enrollment in its pivotal Phase 3 efficacy study (Study 801) of ZX002.

Conference Call and Webcast Scheduled on March 3, 2011 at 4:30pm ET SAN DIEGO, Feb 16, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced it will release financial results for the fourth quarter and full year ended December 31, 2010 after market close on Thursday, March

New Data on Treatment Satisfaction, Efficacy and Tolerability Across Multiple Migraine Attacks SAN DIEGO, Mar 1, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced that data from a Phase 4 clinical study of SUMAVEL(R) DosePro(TM) (sumatriptan injection) Needle-free

Provides 2011 Top-line Guidance Conference Call and Webcast Today, March 3rd, at 4:30 p.m. EST SUMAVEL(R) DosePro(TM) 2010 Adoption Highlights -- Fourth quarter 2010 net product revenue up 27% over third quarter 2010 -- More than 35,200 SUMAVEL DosePro prescriptions were filled from launch through

Newly Issued Patent Covers Product Until 2025 SAN DIEGO, Mar 16, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today confirmed that a recently issued

SAN DIEGO, Apr 12, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced the establishment of a Named Patient Program for SUMAVEL(R) DosePro(R) (sumatriptan injection) Needle-free Delivery System. A Named Patient Program is a mechanism through which physicians can legally

Phase 4 Clinical Data Presented at AAN Annual Meeting SAN DIEGO, Apr 13, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX) today reported clinical data from its Phase 4 open-label, multicenter study of SUMAVEL(R) DosePro (R) (sumatriptan injection) Needle-free Delivery System.

Conference Call and Webcast Scheduled on May 16, 2011 at 4:30pm ET SAN DIEGO, May 4, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced it will release financial results for the first quarter ended March 31, 2011 after market close on Monday, May 16, 2011 at 4:00 p.m.

SAN DIEGO, Calif., May 11, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced that it will present three posters highlighting its proprietary DosePro(R) Needle-free Delivery System at the 2011 American Association of Pharmaceutical Scientists (AAPS) National

Confirms 2011 Financial Guidance Conference Call and Web cast Today, May 16th, at 4:30 p.m. ET SUMAVEL(R) DosePro(R) U.S. Highlights -- First quarter 2011 U.S. net product revenue of $7.5 million, up 10% over the fourth quarter 2010 -- Presented positive Phase 4 results at American Academy of

SAN DIEGO, May 18, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced that it presented three posters highlighting its proprietary DosePro(R) Needle-free Delivery System (DosePro) at the 2011 American Association of Pharmaceutical Scientists (AAPS) National Biotechnology

SAN DIEGO, May 25, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced today that the Company's stockholders have elected Mark Wiggins as a new

New Data Analyzes Efficacy, Tolerability, and Patient Preference for SUMAVEL DosePro Among Current Triptan Users Requiring a Change in Migraine Therapy SAN DIEGO, May 27, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced that additional data from the Company's Phase 4

SUMAVEL® DosePro® Provides Treatment Option for Migraine Patients; Addresses 50% of Oral Triptan Users who are Dissatisfied with their Current Migraine Therapy SAN DIEGO, June 6, 2011 /PRNewswire via COMTEX/ -- Thirty-six million Americans suffer from migraines , leading to more than $20 billion in

SAN DIEGO, Jun 13, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced that Chief Executive Officer Roger L.

Includes an Additional $1.5 Million Equity Investment SAN DIEGO, Jun 30, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced today that it has

  Potential to Address $16 Billion World-Wide Antipsychotics Market SAN DIEGO and CUPERTINO, Calif., July 12, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX - News ), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders

Includes $1.5 Million Equity Investment SAN DIEGO, Jul 18, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced today that it closed its previously

Earnings Call Scheduled for August 10, 2011 at 4:30 p.m. ET SAN DIEGO, Aug 2, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced it will release financial results for the second quarter ended June 30, 2011, after the market closes on Wednesday, August 10, 2011, and will

SAN DIEGO, Aug 4, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced today the publication of its SUMAVEL DosePro (sumatriptan injection)

Zohydro Pivotal Phase 3 Results Expected By End of August Conference Call and Web Cast Today, August 10th, at 4:30 p.m. ET SUMAVEL(R) DosePro(R) Highlights -- Achieved second quarter 2011 U.S. net product revenue of $8.7 million, representing 16% growth over the first quarter -- Zogenix sales force

Conference Call and Webcast Scheduled for 8:30 a.m. ET on August 17, 2011 SAN DIEGO, Aug 16, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today

First Extended-Release Hydrocodone Product Without Acetaminophen NDA Submission Expected by Early 2012 Conference Call and Webcast Today, August 17th, at 8:30 a.m. ET SAN DIEGO, Aug. 17, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing

SAN DIEGO, Aug 24, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX) announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed underwritten public offering of 12,000,000 shares of its common

SAN DIEGO, Sep 16, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX) announced today the pricing of its underwritten public offering of 30,000,000 shares of its common stock at $2.00 per share, before underwriting discounts and commissions.

SAN DIEGO, Sep 19, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced that Stephen J. Farr, Ph.D., President and Chief Operating Officer, and

NDA Submission Remains on Track for Early 2012 SAN DIEGO, Sep 30, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced that it has obtained the

SAN DIEGO, Oct 12, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced today that it will host an investor meeting on Thursday, October 13, 2011,

Conference Call Scheduled for November 10, 2011 at 4:30 pm ET SAN DIEGO, Nov 4, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will

Zogenix Continued Growth of SUMAVEL DosePro Prescriptions and Reported Positive Phase 3 Efficacy Results on Zohydro Conference Call and Webcast Today, November 10th, at 4:30 p.m. ET SUMAVEL(R) DosePro(R) (sumatriptan injection) Highlights -- Increased total prescriptions by 6% sequentially from

SAN DIEGO, Nov 21, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced that Roger L. Hawley, Chief Executive Officer, and Ann Rhoads,

Zohydro NDA Submission on Track SAN DIEGO , Dec. 20, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced that it has concluded its pre-New Drug

SAN DIEGO and Deerfield, Ill. , Dec. 21, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, and Astellas Pharma US, Inc. (Astellas), a U.S.

Evaluating New Co-Promotion Opportunities to Supplement Zogenix U.S. Sales Team Zogenix to Host Conference Call Today at 9:00 am ET SAN DIEGO , Dec. 21, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of

Includes Option for Joint Development of Expanded DosePro(R) Drug Delivery Platform SAN DIEGO and COLUMBUS, Ohio , Jan. 25, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders

SAN DIEGO , Feb. 10, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced that Stephen J. Farr , Ph.D., President and Chief Operating Officer, and Ann

Conference Call Scheduled for March 8, 2012 at 4:30 pm ET SAN DIEGO , Feb. 27, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release

Conference Call and Webcast Today, March 8th, at 4:30 p.m. ET SUMAVEL ® DosePro ® (sumatriptan injection) Highlights Increased total prescriptions to over 71,000 in 2011, a 104% increase over 2010* Increased total prescriptions to over 21,000 in the fourth quarter 2011, 13% higher than the third

Collaboration Opens Possibilities for New DosePro Applications That Offer Validated Needle-Free Subcutaneous Drug Delivery to Bio-Pharma Community SAN DIEGO and COLUMBUS, Ohio, March 29, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX ), a pharmaceutical company commercializing and developing

First NDA Submission for an Extended-Release Hydrocodone Therapy without Acetaminophen SAN DIEGO, May 2, 2012 /PRNewswire via COMTEX/ --Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain,

Conference Call Scheduled for May 14, 2012 at 4:30 pm ET SAN DIEGO , May 3, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release

Reiterates 2012 Financial Guidance Conference Call and Webcast Today, May 14th, at 4:30 p.m. ET SUMAVEL(R) DosePro(R) (sumatriptan injection) Highlights -- Total revenues of $18.3 million achieved in the first quarter 2012 -- Net product revenue increased to $9.9 million in the first quarter 2012,

Potential First Needle-Free Subcutaneous Treatment Option in $2 Billion Long-Acting Injectable Antipsychotic Market SAN DIEGO , May 30, 2012 (GLOBE NEWSWIRE) -- Zogenix Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system

Mallinckrodt Pain Management Sales Force to Begin Promoting SUMAVEL DosePro to Primary Care Customers August 2012 SAN DIEGO , June 7, 2012 (GLOBE NEWSWIRE) -- Zogenix Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system

Patient Screening and Enrollment Underway With Results Anticipated Before Year-End First-in-Class Needle-Free Once-Monthly Formulation Using DosePro® Delivery System SAN DIEGO , July 12, 2012 (GLOBE NEWSWIRE) -- Zogenix Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing

SAN DIEGO , July 16, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced today that the U.S. Food and Drug Administration ( FDA ) has accepted for review the

SAN DIEGO , July 23, 2012 (GLOBE NEWSWIRE) -- Zogenix Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced today that it intends to offer units in an underwritten public offering, with each

SAN DIEGO , July 24, 2012 (GLOBE NEWSWIRE) -- Zogenix Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced today that it has priced an underwritten public offering of 32,500,000 units.

Campaign Targets Biopharmaceutical and Government Potential Out-Licensing Opportunities SAN DIEGO and COLUMBUS, Ohio , July 30, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system

Conference Call Scheduled for August 8, 2012 at 4:30 pm ET SAN DIEGO , July 31, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release

Eliminates Monthly Principal and Interest Payments SAN DIEGO , Aug. 1, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced that it has repaid all

Reiterates 2012 Financial Guidance Conference Call and Webcast Today, August 8th , at 4:30 p.m. ET SUMAVEL ® DosePro ® (sumatriptan injection) Second Quarter 2012 Highlights Successfully retained prescribers called on by the Zogenix sales force, increasing their total prescriptions by 6% over the

SAN DIEGO , Aug. 30, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced that Roger L. Hawley , Chief Executive Officer, and Ann Rhoads , Executive Vice

Features Attack-Specific Treatment Guidelines and Video Resources SAN DIEGO , Sept. 27, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced today the

Presentation at the 2nd Annual Drug Repositioning & Indications Discovery Conference to Demonstrate Increased Adoption of a Standard Therapy Used With DosePro(R) Technology SAN DIEGO , Oct. 23, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and

Conference Call Scheduled for November 8, 2012 at 4:30 pm ET SAN DIEGO , Oct. 25, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release

SAN DIEGO , Nov. 8, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced that the U.S. Food and Drug Administration's ( FDA ) Anesthetic and Analgesic

Growth Continues in Product Sales and Pipeline Remains on Track Conference Call and Webcast Today, November 8th , at 4:30 p.m. ET SUMAVEL ® DosePro ® (sumatriptan injection) Third Quarter 2012 Highlights $8.5 million net product revenue, 5% increase over the second quarter 2012 Zogenix team

Survey Finds RA Patients' Willingness to Accept Prescriptions for Self-Injected Medication Substantially Increases if Needle-Free Option Available COLUMBUS, Ohio and SAN DIEGO, Nov. 13, 2012 (GLOBE NEWSWIRE) -- Battelle, the world's largest independent research and development organization and

SAN DIEGO , Nov. 15, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced that Roger L. Hawley , Chief Executive Officer, and Ann Rhoads , Executive Vice

SAN DIEGO, Nov. 26, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced the appointment of R. Scott Shively to serve as executive vice president and

FDA Advisory Committee Reviewing Zohydro™ ER New Drug Application Zogenix to Host Conference Call at 6:30 pm ET Today SAN DIEGO , Dec. 7, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous

Zogenix to Host Conference Call on Dec. 7, 2012 at 6:30 p.m. ET SAN DIEGO , Dec. 7, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced that the U.S.

Plans to Seek Partner and Accelerate Development of Once-Monthly Subcutaneous Formulation of Risperidone for Schizophrenia SAN DIEGO , Jan. 3, 2013 (GLOBE NEWSWIRE) -- Zogenix Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous

SAN DIEGO , Jan. 7, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced today preliminary unaudited gross product sales for the quarter ended December 31,

SAN DIEGO , Feb. 26, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced that it has been informed by the U.S.

Conference Call Scheduled for March 15, 2013 at 8:30 am ET SAN DIEGO , March 7, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release

Conference Call and Webcast Today, March 15, at 8:30 a.m. ET SUMAVEL ® DosePro ® (sumatriptan injection) Highlights 2012 net product revenue of $35.9 million , up 18% over 2011 Fourth quarter net product revenue of $9.5 million , up 12% over third quarter Increased total prescriptions to over

SAN DIEGO and COLUMBUS, Ohio, Mar 27, 2013 (GLOBE NEWSWIRE via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, and Battelle, the world's largest independent research and

Initiates Efforts to Secure Strategic Development and Commercialization Partner SAN DIEGO , May 2, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced

Conference Call Scheduled for May 9, 2013 at 4:30 pm ET SAN DIEGO , May 3, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release financial

Provides Update on Zohydro ER Conference Call and Webcast Today, May 9 , at 4:30 p.m. ET SUMAVEL ® DosePro ® (sumatriptan injection) First Quarter 2013 Highlights Net product revenue of $7.0 million , reflecting a $1.2 million net adjustment to future product return reserve Generated approximately

DosePro Studies to be Presented at 2013 AAPS National Biotechnology Conference SAN DIEGO and COLUMBUS, Ohio, May 20, 2013 (GLOBE NEWSWIRE via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX) and Battelle Memorial Institute today announced new data supporting the value of the DosePro® needle-free injection

Cost Control Initiatives Extend Cash Runway SAN DIEGO , June 5, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced today initiatives to extend its cash

Supports Patient Education and Empowerment for Managing Multiple Types of Migraine Attacks SAN DIEGO , June 25, 2013 (GLOBE NEWSWIRE) -- In conjunction with National Migraine Awareness Month and in recognition of the significant unmet needs of migraine sufferers, Zogenix, Inc.

Zogenix Sales Force to Begin Promoting Migranal(R) to Its Customer Base of Neurologists and Headache Specialists SAN DIEGO , June 27, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system

Expands Portfolio of Differentiated Migraine Therapies SAN DIEGO , Aug. 1, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced today that its sales force has

Conference Call Scheduled for August 8, 2013 at 4:30 pm ET SAN DIEGO , Aug. 5, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release

Conference Call and Webcast Today, August 8 , at 4:30 p.m. ET SUMAVEL ® DosePro ® (sumatriptan injection) Second Quarter 2013 Highlights Net product revenue of $8.9 million , up 11% over the second quarter 2012 Generated approximately 20,000 total prescriptions Maintained positive quarterly refill

SAN DIEGO , Oct. 1, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, announced that it has been informed today by the U.S.

Conference Call and Webcast on Monday, October 28, at 8:30 a.m. ET SAN DIEGO , Oct. 25, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, today announced that the

SAN DIEGO , Nov. 1, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, today announced that it has entered into a Development and Option Agreement ("D&O

Business Highlights and Milestones Received FDA Approval for Zohydro™ ER (hydrocodone bitartrate), an extended-release oral formulation of hydrocodone without acetaminophen Announced development and option agreement with Altus Formulation Inc. for abuse deterrent formulations of Zohydro ER Began

SAN DIEGO , Nov. 4, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, announced today that it intends to offer and sell $60 million of shares of its common stock in

SAN DIEGO , Nov. 5, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, announced today that it has priced an underwritten public offering of 26,666,667 shares of its

SAN DIEGO , Nov. 12, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, announced today the closing of its previously announced public offering of 30,666,667 shares of

New Long-Term Agreement Reflects Significant Opportunities to Out-License DosePro Technology SAN DIEGO and COLUMBUS, Ohio , Dec. 3, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) and Battelle today announced that they have entered into a new long-term collaborative agreement regarding

SAN DIEGO , Dec. 4, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, today announced that Ann Rhoads , Chief Financial Officer will present at the Oppenheimer 24 th

SAN DIEGO , Dec. 10, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders and pain, announced today that the U.S. Food and Drug Administration ( FDA ) has approved the

SAN DIEGO , Dec. 11, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, reported today that it has issued inducement awards to twelve new non-executive employees.

Additional Clinical and Medical Affairs Leaders Join Zogenix to Support Zohydro(TM) ER Launch SAN DIEGO , Dec. 17, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain,

SAN DIEGO , Dec. 20, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, reported today that it has issued an inducement award to Bradley S.

SAN DIEGO , Jan. 7, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, reported today that it has issued inducement awards to two new non-executive employees.

SAN DIEGO , Jan. 9, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, and Mallinckrodt (NYSE:MNK) announced today that the co-promotion of SUMAVEL ® DosePro ®

SAN DIEGO , Jan. 13, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, announced today preliminary unaudited gross product sales on sales of SUMAVEL ® DosePro ® for

SAN DIEGO , Feb. 4, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, reported today that it has issued inducement awards to fourteen new non-executive employees.

SAN DIEGO , Feb. 4, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, today announced that Stephen J. Farr , Ph.D., President, and Ann Rhoads , Chief Financial

Zogenix in Final Preparations for Early March Market Launch SAN DIEGO , Feb. 11, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, today announced

Experts to Provide Independent Oversight and Recommendations SAN DIEGO , Feb. 12, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced the

Conference Call Scheduled for March 5, 2014 at 4:30 pm ET SAN DIEGO , Feb. 27, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, today announced it

SAN DIEGO , March 5, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, reported today that it has issued inducement awards to 102 new non-executive

Conference Call and Webcast Today, March 5, at 4:30 p.m. ET Business Highlights and Milestones Raised net proceeds of $64.5 million in a public offering of common stock Expanded medical and commercial leadership teams, and sales force to 150 representatives Completed preparations for responsible

SAN DIEGO , March 7, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced that the American Academy of Pain Medicine (AAPM) has presented

SAN DIEGO , March 26, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, announced today that James B.

SAN DIEGO , March 27, 2014 /PRNewswire/ -- We agree with Governor Deval Patrick's intention to curb the epidemic of drug abuse in Massachusetts . However, we are extremely concerned by his unprecedented action with respect to a specific FDA -approved prescription medication.

SAN DIEGO , April 2, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, reported today that it has issued inducement awards to two new non-executive

SAN DIEGO , April 2, 2014 /PRNewswire/ -- We are extremely disappointed that the U.S. Drug Enforcement Administration (DEA) Administrator, as she did in a Congressional hearing today, would repeat misinformation about Zohydro™ ER that has been demonstrated to be false.

SAN DIEGO , April 4, 2014 /PRNewswire/ -- Today, Health and Human Services (HHS) Secretary Kathleen Sebelius , and U.S. Food and Drug Administration ( FDA ) Commissioner Dr. Margaret Hamburg , called for a balanced approach in the fight against prescription drug abuse and preserving the protection

Company Files for Injunction - Prescription Drug Status Should Reside Solely With the FDA SAN DIEGO , April 7, 2014 /PRNewswire/ --  Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS)

SAN DIEGO , April 8, 2014 /PRNewswire/ -- Today Zogenix presented its case in U.S. District Court in Boston requesting an immediate order staying the ban on the U.S. Food and Drug Administration ( FDA )-approved prescription drug product, Zohydro™ ER (hydrocodone bitartrate) extended-release

SAN DIEGO , April 15, 2014 /PRNewswire/ --  Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced that the U.S. District Court in Massachusetts entered an order,

SAN DIEGO , April 23, 2014 /PRNewswire/ -- Zogenix will continue to work to ensure patients suffering from severe chronic pain have access to the FDA -approved medications they need in every state nationwide, including Massachusetts. We are once again disappointed that Governor Patrick would issue

SAN DIEGO , April 24, 2014 /PRNewswire/ -- We at Zogenix  have reviewed the letter to Vermont Governor Peter Shumlin signed by the Center for Lawful Access and Abuse Deterrence ( CLAAD ),  The American Academy of Pain Management and the National Fibromyalgia & Chronic Pain Association , which

Conference Call Scheduled for 8:30 am ET on Thursday, April 24, 2014 SAN DIEGO , April 24, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, announced

Conference Call Scheduled for May 8, 2014 at 4:30 pm ET SAN DIEGO , April 30, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced it will

SAN DIEGO , May 2, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, reported today that it has issued inducement awards to five new non-executive

Conference Call and Webcast Today, May 8, at 4:30 p.m. ET Recent Business Highlights Commercial and medical affairs organization began educational efforts to prescribers and pharmacists for Zohydro™ ER (hydrocodone bitartrate) extended-release capsules the first week in March Continued efforts to

SAN DIEGO , May 19, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, announced today the closing of its previously announced sale of its SUMAVEL ®

SAN DIEGO , May 30, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced that Stephen Farr , Ph.D., President, and Ann Rhoads , Chief

SAN DIEGO , June 2, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, announced today that certain of its executive officers will submit Form 4 filings

SAN DIEGO , June 2, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, reported today that it has issued inducement awards to four new non-executive

SAN DIEGO , June 16, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced that Ann Rhoads , Chief Financial Officer, will be presenting at

Application for Next Generation of Zohydro(R) ER to be Filed by October 2014 SAN DIEGO , July 2, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced an update on its development programs focused on the introduction of abuse deterrent formulations of Zohydro ® ER (hydrocodone

Judge Upholds Prior Decision That State Regulations Cannot Usurp Federal Law SAN DIEGO , July 9, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) today commented on the order issued by the U.S. District Court in Massachusetts upholding its prior decision that imposing regulations to restrict

Covers Fundamental Delivery Profile Needed to Achieve Reliable Subcutaneous Jet Injection SAN DIEGO , July 14, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) announced today the issuance of a new patent, US 8,734,384, from the United States Patent and Trademark Office (USPTO).

Board Commends Comprehensive Surveillance Program, Educational Efforts for Zohydro(R) ER SAN DIEGO , July 17, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous

Conference Call Scheduled for August 5, 2014 at 4:30 pm ET SAN DIEGO , July 22, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced it

SAN DIEGO , Aug. 1, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, today announced that Scott Shively has resigned as Chief Commercial Officer

Conference Call and Webcast Today, August 5, at 4:30 p.m. ET Recent Business Highlights Provided updated timeline for abuse deterrent formulations of Zohydro ® ER (hydrocodone bitartrate) Extended-Release Capsules, CII, with sNDA for first candidate expected to be filed by October, with potential

No Additional Nighttime Dosing and No End-of-Dose Failure, in Most Patients, According to Post-Hoc Analysis Presented at PAINWeek SAN DIEGO , Sept. 2, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of

SAN DIEGO , Sept. 2, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, today announced that Zogenix management will present at the Morgan Stanley

Patients Want Access to a Full Range of FDA-Approved Medications and Pain Relief That Lasts for the Duration of the Prescribed Dosing SAN DIEGO , Sept. 4, 2014 (GLOBE NEWSWIRE) -- When leading health care professionals, chronic pain patients and pain community advocates gathered recently to kick

Moderate and Substantial Levels of Pain Relief Produce the Greatest Functional Benefits With Zohydro(R) ER (hydrocodone bitartrate) Extended-Release Capsules, CII PHOENIX , Sept. 18, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing

SAN DIEGO , Oct. 1, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced it has submitted to the U.S.

Obtains global rights for treatment option in development for Dravet syndrome, a rare and catastrophic form of epilepsy that begins in infancy Plans to initiate Phase 3 clinical studies of Brabafen™ in second quarter of 2015 Conference call and webcast today, October 27 , at 4:30 pm ET SAN DIEGO,

Conference Call Scheduled for November 6, 2014 at 4:30 pm ET SAN DIEGO , Oct. 30, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced it

SAN DIEGO , Oct. 31, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced it has entered into an agreement with Purdue Pharma L.P.

Conference Call and Webcast Today, November 6 , at 4:30 p.m. ET Recent Business Highlights Submitted a supplemental New Drug Application (sNDA) for a modified formulation with potential abuse deterrent properties of Zohydro ® ER (hydrocodone bitartrate) Extended-Release Capsules, CII, on September

SAN DIEGO , Nov. 12, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, today announced that Zogenix management will present at the Stifel 2014

Findings Contribute to Growing Body of Evidence Supporting Efficacy and Safety Profile SAN DIEGO , Dec. 1, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS)

SAN DIEGO , Dec. 3, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, today announced that Stephen Farr , President, and Ann Rhoads , Chief

SAN DIEGO , Jan. 12, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system (CNS) disorders, announced today a business update including recent company highlights,

Zohydro ER With BeadTek(TM) to be Available in the Second Quarter of 2015 SAN DIEGO , Jan. 30, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, today announced that the

SAN DIEGO , Feb. 5, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, today announced that Ann Rhoads , Chief Financial Officer, will present at the Leerink Global

SAN DIEGO , Feb. 10, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, announced today that Renee Tannenbaum , Pharm.D., has been appointed as a new member of the

Conference Call Scheduled for March 10, 2015 at 4:30 pm ET SAN DIEGO , March 2, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, today announced it will release

Conference Call and Webcast to Discuss Fourth Quarter Results and Definitive Agreement to Sell Zohydro ER to Pernix; Scheduled for Today, March 10, at 4:30 p.m. ET Clinical and Regulatory Update Received FDA approval for new formulation of Zohydro ® ER (hydrocodone bitartrate) Extended-Release

Enables planned implementation of new strategic focus to developing a late-stage, high-value CNS pipeline Conference Call and Webcast on Tuesday, March 10 , at 4:30 p.m. ET Agreement Terms: $100 million in upfront consideration comprised of $30 million in cash, $20 million in Pernix common stock

Results Anticipated in Third Quarter 2015, Positioning Zogenix for Potential World-Wide Partnering Opportunities for Relday SAN DIEGO , March 26, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central

Strategic Focus Shifts to Zogenix's High Value Late-Stage CNS Pipeline SAN DIEGO , April 24, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, announced today that it

SAN DIEGO , April 27, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, announced today that it is implementing its succession plan as the Company focuses on advancing

SAN DIEGO , May 4, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, today announced that it will report its financial results for the first quarter ended March 31, 2015

Company Will Host a Conference Call Today at 4:30 p.m. EDT/1:30 p.m. PDT SAN DIEGO , May 11, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, provided a corporate

New data presented at European Paediatric Neurology Society Congress in Vienna, Austria includes 10 patients who continued treatment with low-dose fenfluramine for Dravet syndrome following the original study published in 2012, plus 2 new patients who began treatment in 2011 During 5-year follow-up

SAN DIEGO , June 18, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, announced today that at the annual general meeting of shareholders held earlier today,

SAN DIEGO , July 6, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing unique therapies for the treatment of central nervous system (CNS) disorders, today announced that Stephen J. Farr , Ph.D., President and CEO, will present a corporate

Company Appoints Dr. Gail Farfel as Chief Development Officer and Dr. Thierry Darcis as General Manager, Europe SAN DIEGO , July 6, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system

SAN DIEGO , July 7, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing unique therapies for the treatment of central nervous system (CNS) disorders, today announced that it will host a Key Opinion Leader breakfast focused on Dravet

SAN DIEGO , July 28, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing unique therapies for the treatment of central nervous system (CNS) disorders, announced today that it intends to offer and sell 3,800,000 shares of its common stock in

SAN DIEGO , July 30, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing unique therapies for the treatment of central nervous system (CNS) disorders, announced today that it has priced an underwritten public offering of 4,750,000 shares of

SAN DIEGO , Aug. 3, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, today announced that it will report its financial results for the second quarter ended June 30,

SAN DIEGO , Aug. 5, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing unique therapies for the treatment of central nervous system (CNS) disorders, announced today the closing of its previously announced underwritten public offering of

Company Will Host a Conference Call Today at 4:30 p.m. EDT/1:30 p.m. PDT SAN DIEGO , Aug. 10, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, provided a corporate

SAN DIEGO , Sept. 3, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that Stephen J. Farr , Ph.D., President and CEO, will present a corporate update at the Wells Fargo

SAN DIEGO , Sept. 23, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that Stephen J. Farr , Ph.D., President and CEO, will present a corporate update at the Leerink

Product Candidate Now Phase 3 Ready Company Initiates Efforts to Secure Global Development and Commercialization Partner SAN DIEGO , Sept. 30, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS)

Company Continues to Expect Phase 3 Clinical Program to Begin in Fourth Quarter of 2015 SAN DIEGO , Oct. 19, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced the recent

SAN DIEGO , Nov. 2, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that it will report its financial results for the third quarter ended September 30, 2015 after the

Company Will Host a Conference Call Today at 4:30 p.m. EST/1:30 p.m. PST SAN DIEGO , Nov. 9, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, provided a corporate update, and announced

SAN DIEGO , Nov. 11, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that Stephen J. Farr , Ph.D., President and CEO, will present a corporate update at the Stifel 2015

Three Poster Presentations will Highlight Efficacy, Cardiovascular Safety and Mechanism of Action of Low-Dose Fenfluramine in the Treatment of Dravet Syndrome Zogenix will also Host a Scientific Exhibit Room : "History of the Use of Low-dose Fenfluramine in Pediatric Epilepsy" SAN DIEGO , Nov.

New Clinical Data Presented at 69th Annual American Epilepsy Society Meeting on the Use of Low-Dose Fenfluramine in Managing Seizures Associated With Dravet Syndrome SAN DIEGO , Dec. 7, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the

SAN DIEGO, Dec. 14, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s investigational new drug

SAN DIEGO , Jan. 11, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced the initiation of the first Phase 3 clinical trial for the Company’s lead product candidate, ZX008,

EMERYVILLE, Calif. , Jan. 19, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced receipt of Fast Track designation from the U.S.

EMERYVILLE, Calif. , Feb. 03, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that Stephen J. Farr , Ph.D., President and CEO, and Bradley S.

EMERYVILLE, Calif. , March 04, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that it will report its financial results for the fourth quarter and full-year ended

Company will host a conference call today at 4:30 p.m. EST/1:30 p.m. PST EMERYVILLE, Calif. , March 10, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today provided a corporate update

Podium Presentation to Highlight Efficacy, Cardiovascular Safety, Sleep Quality, and Quality of Life in Patients Receiving Low-Dose Fenfluramine for the Treatment of Dravet Syndrome EMERYVILLE, Calif. , April 21, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc.

EMERYVILLE, Calif. , May 03, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that it will report its financial results for the first quarter ended March 31, 2016 after

Patient and Caregiver Sleep Quality and Quality of Life Data Reported for First Time New Clinical Data Presented at 14 th International Child Neurology Congress on the Use of Low-Dose Fenfluramine in Managing Seizures Associated With Dravet Syndrome EMERYVILLE, Calif.

Company will host a conference call today at 4:30 p.m. EDT/1:30 p.m. PDT EMERYVILLE, Calif. , May 10, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today provided a corporate update

EMERYVILLE, Calif. , May 31, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that Stephen J. Farr , Ph.D., President and CEO, will present a corporate update at the

EMERYVILLE, Calif. , June 07, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced the initiation of the second Phase 3 clinical trial, a multi-national study (Study 1502),

- Interest-only repayment provision results in $10 million increase to Zogenix’s expected cash balance at the end of 2017 - EMERYVILLE, Calif. , June 21, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system

EMERYVILLE, Calif. , Aug. 02, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that it will report its financial results for the second quarter ended June 30,

Company will host a conference call today at 4:30 p.m. EDT/1:30 p.m. PDT EMERYVILLE, Calif. , Aug. 09, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today provided a

Company’s Four Poster Presentations to Focus on ZX008 Open-Label Cohort and Burden of Dravet Syndrome EMERYVILLE, Calif. , Sept. 08, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)

EMERYVILLE, Calif. , Sept. 20, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that Stephen J. Farr , Ph.D., President and CEO, will present a corporate update

EMERYVILLE, Calif. , Oct. 31, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that it will report its financial results for the third quarter ended September

Company will host a conference call today at 4:30 p.m. EST/1:30 p.m. PST EMERYVILLE, Calif. , Nov. 07, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today provided a

EMERYVILLE, Calif. , Nov. 08, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that Stephen J. Farr , Ph.D., President and CEO, will participate in a fireside

EMERYVILLE, Calif. , Nov. 22, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that Gail Farfel , Ph.D., Chief Development Officer, will participate in the

Interim Results of Investigator Initiated Phase 2 study of ZX008 in Lennox Gastaut Syndrome to be Presented Update from Ongoing Open-Label Prospective Study of ZX008 in Dravet Syndrome Will Also be Presented EMERYVILLE, Calif. , Nov. 22, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc.

New Clinical Data Presented at 70 th Annual American Epilepsy Society Meeting Posters Highlighting Potential Protective Effect of ZX008 in Pre-Clinical Model of Sudden Unexpected Death in Epilepsy (SUDEP) and Results of Roundtable Discussions Evaluating Burden of Illness on Caregivers in Dravet

Ann D. Rhoads to Depart Company Following Transition Period; Biopharmaceutical Industry Veteran Michael P. Smith Appointed New CFO EMERYVILLE, Calif. , Jan. 05, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and

Issued Patent is First Covering Company’s Treatment of Seizures Associated with Dravet Syndrome Using Fenfluramine as an Adjunctive Therapy EMERYVILLE, Calif. , Jan. 30, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan

EMERYVILLE, Calif. , Feb. 08, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that Stephen J. Farr , Ph.D., President and CEO, will present a corporate update

Study 1504 Part of Phase 3 Program for ZX008 in Dravet Syndrome Safety and Efficacy Portion of Study Expanded from EU to Include Sites in U.S. and Canada EMERYVILLE, Calif. , Feb. 13, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the

EMERYVILLE, Calif. , Feb. 15, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that Michael P. Smith , Executive Vice President, Chief Financial Officer &

EMERYVILLE, Calif. , March 01, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that the European Commission (EC) has designated ZX008 (fenfluramine) as an

EMERYVILLE, Calif. , March 02, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that it will report its financial results for the fourth quarter and full-year

Top-Line Data for First Phase 3 Study Expected in 3Q 2017 ZX008 Phase 3 Pivotal Study 1504 Initiated – Target Data Readout by End of 2017 Planned Initiation of Phase 3 study of ZX008 in Lennox Gastaut Syndrome in 2H 2017 Company will host a conference call today at 4:30 p.m. EST / 1:30 p.m.

EMERYVILLE, Calif. , March 15, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that Michael P. Smith , Executive Vice President, Chief Financial Officer &

Study 1 Top-Line Data on Track for 3Q 2017 EMERYVILLE, Calif. , April 27, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that the last patient has been

EMERYVILLE, Calif. , April 27, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that it will report its financial results for the first quarter ended March 31,

Completed Enrollment of Study 1, First Phase 3 Clinical Trial of ZX008 in Dravet Syndrome;  Top-Line Results Expected in Third Quarter 2017 IND Accepted by FDA for Phase 3 Clinical Trial of ZX008 in Lennox Gastaut Syndrome Company will host a conference call today at 4:30 p.m. EDT / 1:30 p.m.

New Research Expands Understanding of ZX008 Mechanism in Treating Seizures EMERYVILLE, Calif. , May 22, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that

EMERYVILLE, Calif. , May 31, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that Michael P. Smith , Executive Vice President, Chief Financial Officer &

EMERYVILLE, Calif. , June 22, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced the U.S. Food & Drug Administration ( FDA ) has granted its investigational

EMERYVILLE, Calif. , Aug. 01, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that it will report its financial results for the second quarter ended June 30,

Top-Line Results of First Phase 3 Clinical Trial of ZX008 in Dravet Syndrome Expected in Third Quarter 2017 Second Phase 3 Clinical Trial in Dravet Syndrome, Study 1504, Enrolling According to Plan Orphan Drug Designation Granted by FDA for ZX008 in Lennox Gastaut Syndrome; Phase 3 Clinical Trial

Primary Endpoint Achieved - Statistically Significant Convulsive Seizure Reduction for ZX008 versus Placebo for Adjunctive Treatment of Seizures ZX008 Also Demonstrated Statistical Significance in All Key Secondary Endpoints Zogenix to Host Conference Call Today at 8:30 AM Eastern Time / 5:30 AM

EMERYVILLE, Calif. , Oct. 02, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, announced today that it intends to offer and sell, subject to market and other conditions,

EMERYVILLE, Calif. , Oct. 02, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, announced today that it has priced an underwritten public offering of 6,700,000 shares of its

EMERYVILLE, Calif. , Oct. 05, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, announced today the closing of its previously announced underwritten public offering of 7,705,000

Findings Presented by Zogenix at the NORD Rare Diseases and Orphan Products Breakthrough Summit in Washington, D.C. EMERYVILLE, Calif. , Oct. 16, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system

(GLOBE NEWSWIRE via COMTEX) --Global survey of 584 caregivers of children, young adults and adults with Dravet illustrates the detrimental effect of debilitating, frequent seizures on quality of life and co-morbidities Results suggest a need for more effective antiepileptic treatments EMERYVILLE,

EMERYVILLE, Calif. , Oct. 31, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it will report its financial results for the third quarter ended September 30,

During the third quarter, the Company announced positive top-line results from its Phase 3 Study 1 of ZX008 in patients with Dravet syndrome Study 1 met primary endpoint of reduction in frequency of convulsive seizures (p

EMERYVILLE, Calif. , Nov. 14, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that Stephen J. Farr , Ph.D., President and CEO of Zogenix , will present a corporate

Updated Results of Phase 2 Study of ZX008 in Lennox Gastaut Syndrome to be Presented Data Demonstrating Disease Burden and Negative Impact on Quality of Life of Patients and Families Will Also be Presented EMERYVILLE, Calif. , Nov. 21, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc.

EMERYVILLE, Calif. , Nov. 28, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it will host an update call on Dravet syndrome and the Company’s investigational

EMERYVILLE, Calif. , Nov. 29, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that Stephen J. Farr , Ph.D., President and CEO, and Michael P.

EMERYVILLE, Calif. , Nov. 29, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that the first child has enrolled in the Phase 3 clinical trial for the Company’s lead

ZX008 Patients More Likely to Achieve Clinically Meaningful Reduction in Seizure Frequency Compared to Those on Placebo Parents/Caregivers and Investigators Rated Patients Treated with ZX008 as Very Much Improved or Much Improved in Overall Condition Compared to Placebo Company to Host Call with

Study 1504 Top-Line Data on Track for 2Q 2018 EMERYVILLE, Calif. , Jan. 31, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that the last patient has been randomized

Designation Based on Positive Results from Study 1, the First Pivotal Phase 3 Trial of ZX008 EMERYVILLE, Calif. , Feb. 06, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today

EMERYVILLE, Calif. , Feb. 08, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that Stephen J. Farr , Ph.D., President and CEO, and Michael P.

EMERYVILLE, Calif. , Feb. 27, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it will report its financial results for the fourth quarter and full-year ended

ZX008 Granted Breakthrough Therapy Designation in Dravet syndrome by FDA Last patient randomized into second Phase 3 clinical trial of ZX008 in patients with Dravet syndrome, Study 1504 Initiated global Phase 3 clinical trial for ZX008 in Lennox-Gastaut syndrome EMERYVILLE, Calif.

EMERYVILLE, Calif. , April 11, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that Stephen J. Farr , Ph.D., President and CEO, Gail Farfel , Ph.D., Executive Vice

Efficacy and Safety Data in Patients on ZX008 Who Previously Failed Stiripentol Treatment Prior to Entry into First Phase 3 Trial (Study 1) Comparable to Results from Full Study 1 Population Patients on ZX008 Also Achieved Significant, Clinically Meaningful Reduction in Total Seizure Frequency

ZX008 Patients Experienced Significant Improvements on Select Measures of Quality of Life and Executive Function Compared to Those on Placebo Data Presented During Emerging Therapies Plenary Session at 2018 American Academy of Neurology Annual Meeting EMERYVILLE, Calif.

EMERYVILLE, Calif. , May 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it has issued inducement awards to six new non-executive employees.  The awards

EMERYVILLE, Calif. , May 04, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it will report its financial results for the first quarter ended March 31, 2018 ,

Following receipt of Breakthrough Therapy Designation, conducted successful Type B meeting with FDA confirming adequacy of Phase 3 program for ZX008 NDA in Dravet syndrome Study 1504 fully enrolled with 87 randomized patients; top-line results expected late June/early July On-track to submit U.S.

EMERYVILLE, Calif. , May 14, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that Stephen J. Farr , Ph.D., President and CEO, and Michael P.

EMERYVILLE, Calif. , June 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it has issued inducement awards to four new non-executive employees.  The awards

Ashish Sagrolikar Brings Over 25 Years of Global Pharmaceutical  Sales, Marketing and Operations Experience to Zogenix EMERYVILLE, Calif. , July 02, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system

EMERYVILLE, Calif. , July 02, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it has issued an inducement award to Ashish Sagrolikar, the company’s newly

Primary Endpoint Achieved - Statistically Significant Convulsive Seizure Reduction for ZX008 versus Placebo for Adjunctive Treatment of Seizures ZX008 Also Demonstrated Statistical Significance in All Key Secondary Endpoints U.S. and EU Regulatory Submissions on Track for Fourth Quarter of 2018

EMERYVILLE, Calif. , Aug. 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it will report its financial results for the second quarter ended June 30, 2018 ,

EMERYVILLE, Calif. , Aug. 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it has issued inducement awards to five new non-executive employees.  The awards

Reported positive top-line results from second pivotal Phase 3 trial of ZX008 in patients with Dravet syndrome, Study 1504 Submission of U.S. and EU regulatory filings for ZX008 in Dravet syndrome anticipated by year-end 2018 Actively enrolling global Phase 3 trial of ZX008 for treatment of

EMERYVILLE, Calif. , Aug. 06, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, announced today that it intends to offer and sell, subject to market and other conditions,

EMERYVILLE, Calif. , Aug. 07, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, announced today that it has priced an underwritten public offering of 6,000,000 shares of its

EMERYVILLE, Calif. , Aug. 30, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced new findings from multiple studies assessing the psychological and socioeconomic

67% of Patients Achieved At Least a 50% Reduction in Convulsive Seizures Global Phase 3 Randomized, Controlled Study in LGS Currently Enrolling Patients EMERYVILLE, Calif. , Sept. 04, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the

EMERYVILLE, Calif. , Sept. 04, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it has issued inducement awards to four new non-executive employees.

EMERYVILLE, Calif. , Sept. 25, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that Stephen J. Farr , Ph.D., President and CEO, and Michael P.

EMERYVILLE, Calif. , Oct. 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it has issued inducement awards to three new non-executive employees.

EMERYVILLE, Calif. , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it will report its financial results for the third quarter ended September 30,

EMERYVILLE, Calif. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that Stephen J. Farr , Ph.D., President and CEO, and Michael P.

Reported positive top-line results from second pivotal Phase 3 trial of FINTEPLA ® (ZX008) in patients with Dravet syndrome, Study 1504 Initiated rolling NDA submission to FDA for FINTEPLA Continued to advance enrollment of global Phase 3 trial of FINTEPLA for treatment of Lennox-Gastaut syndrome,

Full Results from Second Pivotal Phase 3 Trial of FINTEPLA ® (ZX008) in Dravet Syndrome (Study 1504) New Long-Term Efficacy and Safety Data from Open-Label Extension Trial (Study 1503) Studies on the Impact of Severe Epilepsy on Quality of Life for Patients and Families EMERYVILLE, Calif. , Nov.

EMERYVILLE, Calif. , Nov. 27, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that Michael P. Smith , Executive Vice President, Chief Financial Officer, Treasurer

EMERYVILLE, Calif. , Nov. 29, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare diseases, today announced that it will host an Investor Update Lunch on FINTEPLA® (ZX008) on Monday, December 3, 2018 , from 12:00 PM to 2:00

Data Presented During Late-Breaker Session at 72 nd   American Epilepsy Society Annual Meeting Additional New Analyses Underscore Psychosocial Burden on Family EMERYVILLE, Calif. , Dec. 02, 2018 (GLOBE NEWSWIRE) --   Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the

Positive Data from Second Pivotal Phase 3 Trial (Study 1504) Consistent with Results of First Phase 3 Trial in Showing Highly Significant Convulsive Seizure Reduction for FINTEPLA versus Placebo Clinically Meaningful Reduction in Convulsive Seizure Frequency for FINTEPLA Maintained Over Phase 3

EMERYVILLE, Calif. , Dec. 03, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it has issued inducement awards to three new non-executive employees.   The